Gregory Piazza

Gregory Piazza

Auto-generated profile, based on publicly available information

Gregory Piazza

Thrombosis Research Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2015 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
GPGregory Piazza
Gregory Piazza
BHBenjamin Hohlfelder
Benjamin Hohlfelder
MJMichael R. Jaff
Michael R. Jaff
KOKenneth Ouriel
Kenneth Ouriel
TETod C. Engelhardt
Tod C. Engelhardt
SGSamuel Z. Goldhaber
Samuel Z. Goldhaber

1 November 2020 in JACC
Verified
Journal Article
Open access
GPGregory Piazza
Gregory Piazza
UCUmberto Campia
Umberto Campia
SHShelley Hurwitz
Shelley Hurwitz
JSJulia E. Snyder
Julia E. Snyder
SRSamantha M. Rizzo
Samantha M. Rizzo
SGSamuel Z. Goldhaber
Samuel Z. Goldhaber
Cardiovascular complications, including myocardial infarction, ischemic stroke, and pulmonary embolism, represent an important source of adverse outcomes in coronavirus disease-2019 (COVID-19). To assess the frequency of arterial and venous thromboembolic disease, risk factors, prevention and management patterns, and outcomes in patients with COVID-19, the authors designed a multicenter, observational cohort study. We analyzed a retrospective cohort of 1,114 patients with COVID-19 diagnosed through our Mass General Brigham integrated health network. The total cohort was analyzed by site of care: intensive care (n = 170); hospitalized nonintensive care (n = 229); and outpatient (n = 715). The primary study outcome was a composite of adjudicated major arterial or venous thromboembolism. Patients with COVID-19 were 22.3% Hispanic/Latinx and 44.2% non-White. Cardiovascular risk factors of hypertension (35.8%), hyperlipidemia (28.6%), and diabetes (18.0%) were common. Prophylactic anticoagulation was prescribed in 89.4% of patients with COVID-19 in the intensive care cohort and 84.7% of those in the hospitalized nonintensive care setting. Frequencies of major arterial or venous thromboembolism, major cardiovascular adverse events, and symptomatic venous thromboembolism were highest in the intensive care cohort (35.3%, 45.9%, and 27.0 %, respectively) followed by the hospitalized nonintensive care cohort (2.6%, 6.1%, and 2.2%, respectively) and the outpatient cohort (0% for all). Major arterial or venous thromboembolism, major adverse cardiovascular events, and symptomatic venous thromboembolism occurred with high frequency in patients with COVID-19, especially in the intensive care setting, despite a high utilization rate of thromboprophylaxis.

27 April 2010 in Circulation
Verified
Journal Article
Open access
PDF file
GPGregory Piazza
Gregory Piazza
MCMark A. Creager
Mark A. Creager

5 January 2016 in Circulation
Verified
Journal Article
Closed access
PDF file
DDDavid M. Dudzinski
David M. Dudzinski
GPGregory Piazza
Gregory Piazza

20 January 2015 in Circulation
Verified
Journal Article
Closed access
PDF file
EKEthan Kosova
Ethan Kosova
BBBrian Bergmark
Brian Bergmark
GPGregory Piazza
Gregory Piazza

1 November 2020 in JACC
Verified
Journal Article
Closed access
GPGregory Piazza
Gregory Piazza